Nephrolithiasis associated with embolization material, Lipiodol®, following embolization of large renal angiomyolipoma
Chen I, Perkins SQ, Schwartz SE, and Leavitt D. Nephrolithiasis associated with embolization material, Lipiodol®, following embolization of large renal angiomyolipoma. Urol Case Rep 2022; 40:101910.
Urol Case Rep
Angiomyolipoma (AML) is a benign renal mass that can be treated with nephron sparing surgery or transarterial embolization. Embolization has been favored due to efficacy and safety profile. This case demonstrates a previously undocumented phenomenon of AML treated with transarterial embolization using Lipiodol® (Guerbet LLC, Princeton, NJ) resulting in nephrolithiasis and retention of Lipiodol® two years after original embolization. Although Lipiodol®-based embolization has not been shown to cause nephrolithiasis, it may have been the nidus for stone formation, and this is an important potential complication worthy of further study.